Table 6.
Correlation between nitric oxide (nitrate and nitrite) serum levels and clinical and radiological parameters measured in all multiple sclerosis patients and in groups under first and second line of disease-modifying therapies.
| NOx a [µM] | MSf patients | LI | LII |
|---|---|---|---|
| N | 63 | 44 | 19 |
| EDSSb [points] | −0.19 | −0.10 | −0.29 |
| ARRc [n] | −0.007 | −0.12 | −0.19 |
| T2 MRId lesions (from the time of diagnosis) [n] | −0.05 | 0.11 | −0.28 |
| New MRI lesions (within the last year) [n] | −0.05 | 0.13 | −0.41 |
| Gd+e MRI lesions (from the time of diagnosis) [n] | −0.14 | −0.03 | −0.42 |
| New Gd+ MRI lesions (within the last year) [n] | −0.22 | 0.19 | −0.42 |
∗ p > 0.05 in all analysis.
A: nitric oxide (nitrite and nitrate); b: Expanded Disability Status Scale. C: annual relapse rate; d: magnetic resonance imaging; e: Gadovist; f: multiple sclerosis.